Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$40.65
-0.42-1.02%
At close: -
$41.04
0.390.96%
After Hours: Jun 20, 5:38 PM EDT
Comments
Loading...
Tarsus Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:TARS | Benzinga
Tarsus Pharmaceuticals Inc has a consensus price target of $64.25 based on the ratings of 8 analysts. The high is $84 issued by Guggenheim on May 2, 2025. The low is $44 issued by William Blair on July 18, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Goldman Sachs, and Guggenheim on May 27, 2025, May 5, 2025, and May 2, 2025, respectively. With an average price target of $69 between HC Wainwright & Co., Goldman Sachs, and Guggenheim, there's an implied 68.13% upside for Tarsus Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Goldman Sachs
Guggenheim
Jefferies
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Tarsus Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/27/2025 | Buy Now | 75.44% | HC Wainwright & Co. | Matthew Caufield38% | → $72 | Assumes | → Buy | Get Alert |
| 05/05/2025 | Buy Now | 24.27% | Goldman Sachs | Andrea Tan40% | $46 → $51 | Maintains | Neutral | Get Alert |
| 05/02/2025 | Buy Now | 104.68% | Guggenheim | Eddie Hickman50% | $78 → $84 | Maintains | Buy | Get Alert |
| 03/06/2025 | Buy Now | 41.33% | Jefferies | Anthony Petrone64% | $54 → $58 | Maintains | Buy | Get Alert |
| 02/26/2025 | Buy Now | 90.06% | Guggenheim | Eddie Hickman50% | $75 → $78 | Maintains | Buy | Get Alert |
| 02/26/2025 | Buy Now | 77.88% | HC Wainwright & Co. | Oren Livnat60% | $73 → $73 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2025 | Buy Now | 46.2% | Barclays | Balaji Prasad55% | $62 → $60 | Maintains | Overweight | Get Alert |
| 02/24/2025 | Buy Now | — | Guggenheim | Eddie Hickman50% | — | Reiterates | Buy → Buy | Get Alert |
| 02/10/2025 | Buy Now | — | Guggenheim | Eddie Hickman50% | — | Reiterates | Buy → Buy | Get Alert |
| 01/27/2025 | Buy Now | 51.07% | Barclays | Balaji Prasad55% | $60 → $62 | Maintains | Overweight | Get Alert |
| 01/22/2025 | Buy Now | 75.44% | Oppenheimer | Francois Brisebois39% | $65 → $72 | Maintains | Outperform | Get Alert |
| 11/15/2024 | Buy Now | -0.1% | Goldman Sachs | Andrea Tan40% | $36 → $41 | Maintains | Neutral | Get Alert |
| 11/14/2024 | Buy Now | 58.38% | Oppenheimer | Francois Brisebois39% | $63 → $65 | Maintains | Outperform | Get Alert |
| 08/09/2024 | Buy Now | 53.51% | Oppenheimer | Francois Brisebois39% | $61 → $63 | Reiterates | Outperform → Outperform | Get Alert |
| 05/13/2024 | Buy Now | 48.64% | HC Wainwright & Co. | Oren Livnat60% | $57 → $61 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 46.2% | Barclays | Balaji Prasad55% | $50 → $60 | Maintains | Overweight | Get Alert |
| 05/09/2024 | Buy Now | 48.64% | Oppenheimer | Francois Brisebois39% | $59 → $61 | Maintains | Outperform | Get Alert |
| 03/06/2024 | Buy Now | 7.21% | Jefferies | Anthony Petrone64% | $30 → $44 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | -26.9% | Goldman Sachs | Andrea Tan40% | $19 → $30 | Maintains | Neutral | Get Alert |
| 02/28/2024 | Buy Now | 38.89% | HC Wainwright & Co. | Oren Livnat60% | $50 → $57 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 21.83% | Barclays | Balaji Prasad55% | $40 → $50 | Maintains | Overweight | Get Alert |
| 02/28/2024 | Buy Now | 43.76% | Oppenheimer | Francois Brisebois39% | $55 → $59 | Reiterates | Outperform → Outperform | Get Alert |
| 11/20/2023 | Buy Now | -53.7% | Goldman Sachs | Andrea Tan40% | → $19 | Initiates | → Neutral | Get Alert |
| 11/10/2023 | Buy Now | 21.83% | HC Wainwright & Co. | Oren Livnat60% | $42 → $50 | Maintains | Buy | Get Alert |
| 09/11/2023 | Buy Now | 19.4% | Guggenheim | Eddie Hickman50% | $46 → $49 | Maintains | Buy | Get Alert |
| 08/14/2023 | Buy Now | 12.09% | Guggenheim | Eddie Hickman50% | → $46 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | 2.34% | HC Wainwright & Co. | Oren Livnat60% | $50 → $42 | Maintains | Buy | Get Alert |
| 07/26/2023 | Buy Now | 21.83% | HC Wainwright & Co. | Oren Livnat60% | $44 → $50 | Maintains | Buy | Get Alert |
| 07/18/2023 | Buy Now | 7.21% | William Blair | — | → $44 | Initiates | → Outperform | Get Alert |
| 06/26/2023 | Buy Now | 7.21% | HC Wainwright & Co. | Oren Livnat60% | $40 → $44 | Maintains | Buy | Get Alert |
| 06/16/2023 | Buy Now | 2.34% | Guggenheim | Eddie Hickman50% | $40 → $42 | Maintains | Buy | Get Alert |
| 05/18/2023 | Buy Now | — | Guggenheim | Eddie Hickman50% | — | Initiates | → Buy | Get Alert |
| 05/08/2023 | Buy Now | 4.78% | Oppenheimer | Francois Brisebois39% | → $43 | Reiterates | → Outperform | Get Alert |
| 03/15/2023 | Buy Now | -2.53% | HC Wainwright & Co. | Oren Livnat60% | → $40 | Reiterates | → Buy | Get Alert |
| 08/01/2022 | Buy Now | -2.53% | Barclays | Balaji Prasad55% | → $40 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Tarsus Pharmaceuticals (TARS) stock?
The latest price target for Tarsus Pharmaceuticals (NASDAQ:TARS) was reported by HC Wainwright & Co. on May 27, 2025. The analyst firm set a price target for $72.00 expecting TARS to rise to within 12 months (a possible 75.44% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Tarsus Pharmaceuticals (TARS)?
The latest analyst rating for Tarsus Pharmaceuticals (NASDAQ:TARS) was provided by HC Wainwright & Co., and Tarsus Pharmaceuticals their buy rating.
When was the last upgrade for Tarsus Pharmaceuticals (TARS)?
There is no last upgrade for Tarsus Pharmaceuticals
When was the last downgrade for Tarsus Pharmaceuticals (TARS)?
There is no last downgrade for Tarsus Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Tarsus Pharmaceuticals (TARS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tarsus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tarsus Pharmaceuticals was filed on May 27, 2025 so you should expect the next rating to be made available sometime around May 27, 2026.
Is the Analyst Rating Tarsus Pharmaceuticals (TARS) correct?
While ratings are subjective and will change, the latest Tarsus Pharmaceuticals (TARS) rating was a with a price target of $0.00 to $72.00. The current price Tarsus Pharmaceuticals (TARS) is trading at is $41.04, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
